TY  - GEN
AU  - Horváth, Zsolt
AU  - Gálffy, Gabriella (kerekasztal-résztvevő)
AU  - Hitre, Erika
AU  - Torday, László (kerekasztal-résztvevő)
AU  - Géczi, Lajos
TI  - Az elsővonalas immunterápia választásának aktualitásai
PY  - 2023
UR  - https://m2.mtmt.hu/api/publication/34406270
ID  - 34406270
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Kiss, Zoltán
AU  - Kocsis, Judit
AU  - Nikolényi, Alíz
AU  - Horváth, Zsolt
AU  - Knollmajer, Kata
AU  - Benedek, Angela
AU  - Várnai, Máté
AU  - Polányi, Zoltán
AU  - Kovacs, Andrea Krisztina
AU  - Berta, Andrea
AU  - Köveskuti, István
AU  - Karamousouli, Eugenia
AU  - Szabó, Tamás G.
AU  - Rokszin, György Aurél
AU  - Bajcsayné Fábián, Ibolya
AU  - Bartókné Tamás, Renáta
AU  - Surján, Orsolya
AU  - Fürtős, Diána
AU  - Surján, György
AU  - Kenessey, István
AU  - Wéber, András
AU  - Barcza, Zsófia
AU  - Berki, Tamás
AU  - Vokó, Zoltán
AU  - Dózsa, Csaba
AU  - Dank, Magdolna
AU  - Boér, Katalin
TI  - Opposite trends In incidence of breast cancer in young and old female cohorts in Hungary and the impact of the COVID-19 pandemic: a nationwide study between 2011–2020
JF  - FRONTIERS IN ONCOLOGY
J2  - FRONT ONCOL
VL  - 13
PY  - 2023
PG  - 12
SN  - 2234-943X
DO  - 10.3389/fonc.2023.1182170
UR  - https://m2.mtmt.hu/api/publication/34105055
ID  - 34105055
N1  - Funding Agency and Grant Number: MSD Pharma Hungary
            Funding text: Authors ZK, ZP, MV, ABen, ABer, TS, EK, KKn, KKo, IKe andTS were employed by the company MSD Pharma Hungary. ZV areemployees of Semmelweis University. Semmelweis University received a grant from MSD Pharma Hungary to contribute to this research. GR and IF are employees of RxTarget Ltd. and ZB isemployed of Syntesia Ltd. where their contribution to this project was financially compensated.The remaining authors declare that the research was conductedin the absence of any commercial orfinancial relationships thatcould be construed as a potential conflict of interest.The authors declare that this study received funding from MSD Pharma Hungary. The funder had the following involvement withthe study: in study design, data collection and analysis, decision topublish, and preparation of the manuscript
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Oliveira, Mafalda
AU  - Pominchuck, Denys
AU  - Nowecki, Zbigniew
AU  - Hamilton, Erika
AU  - Kulyaba, Yaroslav
AU  - Andabekov, Timur
AU  - Hotko, Yevhen
AU  - Melkadze, Tamar
AU  - Nemsadze, Gia
AU  - Neven, Patrick
AU  - Semegen, Yuriy
AU  - Vladmirov, Vladmir
AU  - Zamagni, Claudio
AU  - Denys, Hannelore
AU  - Forget, Frederic
AU  - Horváth, Zsolt
AU  - Nesterova, Alfiya
AU  - Bennett, Maxine
AU  - Kirova, Bistra
AU  - Klinowska, Teresa
AU  - Lindemann, Justin
AU  - Lissa, Delphine
AU  - Mathewson, Alastair
AU  - Morrow, Christopher
AU  - Traugottova, Zuzana
AU  - Van Zyl, Ruaan
AU  - Arkania, Ekaterine
TI  - Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial
JF  - CANCER RESEARCH
J2  - CANCER RES
VL  - 83
PY  - 2023
IS  - 5_Supplement
SP  - GS3-02
EP  - GS3-02
SN  - 0008-5472
DO  - 10.1158/1538-7445.SABCS22-GS3-02
UR  - https://m2.mtmt.hu/api/publication/34104957
ID  - 34104957
AB  - Background Camizestrant (C), a next-generation oral selective estrogen receptor (ER) antagonist and degrader (ngSERD) has shown promising clinical activity in ER+ breast cancer (BC) in the Phase 1 SERENA-1 study1,2 with a dose-dependent safety profile. The Phase 2 randomized SERENA-2 study (NCT04214288) initially assessed three doses of C vs fulvestrant (F) in post-menopausal women with ER+ HER2˗ BC with disease recurrence or progression after ≤1 endocrine therapy (ET) in the advanced setting.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Galffy, G.
AU  - Lugowska, I.
AU  - Poddubskaya, E.V.
AU  - Cho, B.C.
AU  - Ahn, M.-J.
AU  - Han, J.-Y.
AU  - Su, W.-C.
AU  - Hauke, R.J.
AU  - Dyar, S.H.
AU  - Lee, D.H.
AU  - Serwatowski, P.
AU  - Estelles, D.L.
AU  - Holden, V.R.
AU  - Kim, Y.J.
AU  - Vladimirov, V.
AU  - Horváth, Zsolt
AU  - Ghose, A.
AU  - Goldman, A.
AU  - di, Pietro A.
AU  - Wang, J.
AU  - Murphy, D.A.
AU  - Alhadab, A.
AU  - Laskov, M.
TI  - A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
JF  - ESMO OPEN
J2  - ESMO OPEN
VL  - 8
PY  - 2023
IS  - 3
SN  - 2059-7029
DO  - 10.1016/j.esmoop.2023.101173
UR  - https://m2.mtmt.hu/api/publication/33929577
ID  - 33929577
N1  - Export Date: 31 May 2023            
            Correspondence Address: Galffy, G.; Pulmonology Hospital Törökbálint, 70 Munkácsy Mihály Street, Hungary; email: galffy.gabriella@torokbalintkorhaz.hu            
            Chemicals/CAS: alanine aminotransferase, 9000-86-6, 9014-30-6; amylase, 9000-90-2, 9000-92-4, 9001-19-8; aspartate aminotransferase, 9000-97-9; avelumab, 1537032-82-8; axitinib, 319460-85-0; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; triacylglycerol lipase, 9001-62-1            
            Tradenames: ACE ImmunoID, personalis; SP263, cell carta            
            Manufacturers: cell carta; personalis; Visiopharm
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Rubovszky, Gábor
AU  - Kocsis, Judit
AU  - Boér, Katalin
AU  - Chilingirova, Nataliya
AU  - Dank, Magdolna
AU  - Kahán, Zsuzsanna
AU  - Kaidarova, Dilyara
AU  - Kövér, Erika
AU  - Krakovská, Bibiana Vertáková
AU  - Máhr, Károly
AU  - Mriňáková, Bela
AU  - Pikó, Béla
AU  - Božović-Spasojević, Ivana
AU  - Horváth, Zsolt
TI  - Corrigendum : Systemic treatment of breast cancer. 1st Central-Eastern European professional Consensus Statement on breast cancer
JF  - PATHOLOGY AND ONCOLOGY RESEARCH
J2  - PATHOL ONCOL RES
VL  - 29
PY  - 2023
PG  - 2
SN  - 1219-4956
DO  - 10.3389/pore.2023.1610954
UR  - https://m2.mtmt.hu/api/publication/33647465
ID  - 33647465
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Gulácsi, László
AU  - Békássy, Sz.
AU  - Bittner, Nóra
AU  - Feith, Helga Judit
AU  - Ficzere, A.
AU  - Horváth, Lajos
AU  - Horváth, Zsolt
AU  - Tóth, I.
AU  - Zrubka, Zs.
AU  - Tóth, Erika
AU  - Kovács, L. Gábor
TI  - Személyre szabott orvoslás és egészségügy. hol tartunk, merre menjünk?
TS  - hol tartunk, merre menjünk?
JF  - ORVOSI HETILAP
J2  - ORV HETIL
VL  - 164
PY  - 2023
IS  - 6
SP  - 202
EP  - 209
PG  - 8
SN  - 0030-6002
DO  - 10.1556/650.2023.32711
UR  - https://m2.mtmt.hu/api/publication/33630503
ID  - 33630503
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - CHAP
AU  - Ruzsa, Ágnes
AU  - Horváth, Zsolt
ED  - Csikós, Ágnes
TI  - Onkológiai kezelések a palliatív ellátásban
T2  - Palliatív ellátás
PB  - Medicina Könyvkiadó
CY  - Budapest
SN  - 9789632268453
PY  - 2022
SP  - 341
EP  - 351
PG  - 11
UR  - https://m2.mtmt.hu/api/publication/32956307
ID  - 32956307
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Rubovszky, Gábor
AU  - Kocsis, Judit
AU  - Boér, Katalin
AU  - Chilingirova, Nataliya
AU  - Dank, Magdolna
AU  - Kahán, Zsuzsanna
AU  - Kaidarova, Dilyara
AU  - Kövér, Erika
AU  - Krakovská, Bibiana Vertáková
AU  - Máhr, Károly
AU  - Mriňáková, Bela
AU  - Pikó, Béla
AU  - Božović-Spasojević, Ivana
AU  - Horváth, Zsolt
ED  - Krenács, Tibor / Collaborator
ED  - Kulka, Janina / Collaborator
ED  - Dank, M / Collaborator
ED  - Polgár, Csaba / Collaborator
ED  - Kapitány, Zsuzsanna / Collaborator
ED  - Koncz, Zsuzsa / Collaborator
TI  - Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer
JF  - PATHOLOGY AND ONCOLOGY RESEARCH
J2  - PATHOL ONCOL RES
VL  - 28
PY  - 2022
PG  - 26
SN  - 1219-4956
DO  - 10.3389/pore.2022.1610383
UR  - https://m2.mtmt.hu/api/publication/32946435
ID  - 32946435
N1  - Funding Agency and Grant Number: Central Eastern European Academy of Oncology Foundation; National Institute of Oncology
            Funding text: The publication fee is covered by funding of the Central Eastern European Academy of Oncology Foundation, National Institute of Oncology 1122 Budapest Rath Gy. u 7-9.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Reinmuth, Niels
AU  - Juan-Vidal, Oscar
AU  - Horváth, Zsolt
AU  - Kowalski, Dariusz
AU  - Kryzhanivska, Anna
AU  - Csánky, Eszter
AU  - Gálffy, Gabriella
AU  - Bryl, Maciej
AU  - Vicente, David
AU  - Vynnychenko, Ihor
AU  - Pápai-Székely, Zsolt
AU  - Armstrong, Jon
AU  - Dalvi, Tapashi
AU  - Shrestha, Yashaswi
AU  - Xie, Mingchao
AU  - Jiang, Haiyi
AU  - Bondarenko, Igor
TI  - Abstract CT533: Durvalumab (D) plus tremelimumab (T) in platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC): Efficacy, safety and ctDNA dynamics from Arm A of the phase 2 BALTIC study
JF  - CANCER RESEARCH
J2  - CANCER RES
VL  - 82
PY  - 2022
IS  - 12_Supplement
SP  - CT533
EP  - CT533
SN  - 0008-5472
DO  - 10.1158/1538-7445.AM2022-CT533
UR  - https://m2.mtmt.hu/api/publication/32946401
ID  - 32946401
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
ED  - Hahn, Oszkár / Collaborator
ED  - Szijártó, Attila / Collaborator
ED  - Pekli, Damján / Collaborator
ED  - Fülöp, András / Collaborator
ED  - Kokas, Bálint András / Collaborator
ED  - Bárdos, Dávid / Collaborator
ED  - Andras, Csilla / Collaborator
ED  - Bartek, Peter / Collaborator
ED  - Battyáni, István / Collaborator
ED  - Bezsilla, Janos / Collaborator
ED  - Bodoky, György / Collaborator
ED  - Bursics, Attila / Collaborator
ED  - Dank, Magdolna / Collaborator
ED  - Dankovics, Zsofia / Collaborator
ED  - Deák, Pál Ákos / Collaborator
ED  - Dede, Kristof / Collaborator
ED  - Demeter, Gyula / Collaborator
ED  - Doros, Attila / Collaborator
ED  - Dudás, Ibolyka / Collaborator
ED  - Egyed, Zsofia / Collaborator
ED  - Farkas, Róbert / Collaborator
ED  - Gerlei, Zsuzsanna / Collaborator
ED  - Györke, Tamás / Collaborator
ED  - Hagymási, Krisztina / Collaborator
ED  - Hitre, Erika / Collaborator
ED  - Hőhn, József / Collaborator
ED  - Jancsik, Viktor / Collaborator
ED  - Káposztás, Zsolt / Collaborator
ED  - Kiraly, Istvan / Collaborator
ED  - Loderer, Tamas / Collaborator
ED  - Nagy, Endre / Collaborator
ED  - Olah, Attila / Collaborator
ED  - Pajor, Peter / Collaborator
ED  - Papp, András / Collaborator
ED  - Pár, Gabriella / Collaborator
ED  - Patyanik, Mihaly / Collaborator
ED  - Petrányi, Ágota Eszter / Collaborator
ED  - Petri, András / Collaborator
ED  - Piros, László / Collaborator
ED  - Schuller, Janos / Collaborator
ED  - Sikorszki, Laszlo / Collaborator
ED  - Szabó, József / Collaborator
ED  - Székely, Eszter / Collaborator
ED  - Szombati, Andrea / Collaborator
ED  - Torday, László / Collaborator
ED  - Toth, Judit / Collaborator
ED  - Toth, Lajos Barna / Collaborator
ED  - Dósa, Edit / Collaborator
ED  - Harsányi, László / Collaborator
ED  - Horváth, Zsolt / Collaborator
ED  - István, Gábor / Collaborator
ED  - Landherr, Laszlo / Collaborator
ED  - Lázár, György ifj / Collaborator
ED  - Lengyel, Gabriella / Collaborator
ED  - Lovey, Jozsef / Collaborator
ED  - Mangel, László Csaba / Collaborator
ED  - Maurovich-Horvat, Pál / Collaborator
ED  - Nemes, Balázs / Collaborator
ED  - Palkó, András / Collaborator
ED  - Schaff, Zsuzsa / Collaborator
ED  - Szalay, Ferenc / Collaborator
ED  - Szűcs, Ákos / Collaborator
ED  - Vereczkei, András / Collaborator
ED  - Lazar, Istvan / Collaborator
TI  - A hepatocellularis carcinoma komplex kezelése. Konszenzuskonferencia, Budapest, 2021. április 24.
TS  - Konszenzuskonferencia, Budapest, 2021. április 24.
JF  - ORVOSI HETILAP
J2  - ORV HETIL
VL  - 162
PY  - 2022
IS  - Suppl. 2.
SP  - 2
EP  - 31
PG  - 30
SN  - 0030-6002
DO  - 10.1556/650.2021.32431
UR  - https://m2.mtmt.hu/api/publication/32704404
ID  - 32704404
LA  - Hungarian
DB  - MTMT
ER  -